GLP-1 Agonist Metabolic peptide

Semaglutide

15,000 ฿ · 5mg vial

What it is

Semaglutide is a long-acting synthetic analog of GLP-1 (glucagon-like peptide-1), a hormone naturally released by the intestine after eating. It binds the GLP-1 receptor with high affinity and is structurally modified to resist degradation, allowing for once-weekly dosing in its pharmaceutical form.

Pharmaceutical history

Developed by Novo Nordisk. Approved by the FDA in 2017 for type 2 diabetes (brand name Ozempic) and in 2021 for chronic weight management (Wegovy). Oral and injectable forms exist; this vial is for reconstitution and subcutaneous use.

How it works (simply)

Why customers ask about it

Sustained, significant body weight reduction in clinical trials (typically 10–15% over 60+ weeks in non-diabetic populations on the highest doses). Often the first thing a customer asks for when their goal is fat loss.

Important

This is a real prescription medication in most countries. Common side effects include nausea, GI upset, and constipation, especially during dose escalation. Customers with personal or family history of medullary thyroid cancer or MEN2 are contraindicated. Sold as a research-purpose product; for any medical decision, please consult a physician.

← Back to catalog